Sangamo Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and a Favorable Safety Profile

Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation